Stocks in Play

Medicenna Therapeutics Corp.

10:11 AM EST - Medicenna Therapeutics Corp. : Today announced dosing of the first patient in the Phase 2 monotherapy dose expansion portion of the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study evaluating MDNA11, a long-acting, beta-only interleukin-2 (IL-2) super-agonist. Medicenna Therapeutics Corp. shares T.MDNA are trading up $0.02 at $0.38.